# OnCo record mantle-cell-lymphoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/mantle-cell-lymphoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "mantle-cell-lymphoma" ;
  schema:name "Mantle cell lymphoma"@en ;
  schema:description "An uncommon B-cell lymphoma driven by cyclin D1 that used to behave badly in almost everyone. BTK inhibitors, CAR-T and now BCL2 drugs have changed it from chemotherapy-plus-transplant to targeted combinations."@en ;
  schema:url <https://onco.cc/cancers/mantle-cell-lymphoma/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Mantle_cell_lymphoma> ;
  owl:sameAs <http://www.wikidata.org/entity/Q268713> ;
  schema:citation <https://doi.org/10.1016/S0140-6736(24)00184-3>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1480>, <https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq>, <https://lymphoma-action.org.uk/information-and-support/support-you/helpline-services>, <https://lymphoma-action.org.uk/information-and-support/tests-scans-and-lymphoma-staging/questions-ask-your-medical-team-about-lymphoma>, <https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/follow-after-lymphoma-treatment>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/infections-risk-and-prevention>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/neutropenia-low-neutrophils>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/cancer-related-fatigue>, <https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/day-day-living/lymphoma-work-and-you>, <https://www.maggies.org/support-and-information/>, <https://lymphoma-action.org.uk/information-and-support/lymphoma-treatment/active-monitoring-watch-and-wait>, <https://lymphoma-action.org.uk/information-and-support/lymphoma-treatment/car-t-cell-therapy>, <https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/lymphoma-comes-back-relapses-or-doesnt-respond>, <https://www.macmillan.org.uk/cancer-information-and-support/lymphoma/non-hodgkin-lymphoma> ;
  onco:tag "gap-fill", "haematologic" ;
  onco:related <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/cancers/marginal-zone-lymphoma/>, <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/waldenstrom/>, <https://onco.cc/biomarkers/tp53-del17p/>, <https://onco.cc/biomarkers/btk-c481s/>, <https://onco.cc/biomarkers/bcl2-g101v/>, <https://onco.cc/terms/cyclin-d1-t11-14/>, <https://onco.cc/roadmaps/lymphoma-roadmap/>, <https://onco.cc/ideas/lymphoma-ev-fixed-duration-chemotherapy-free-first-line/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/palliative-care/>, <https://onco.cc/technologies/psycho-oncology/>, <https://onco.cc/technologies/peer-support-groups/>, <https://onco.cc/technologies/survivorship-care-plan/>, <https://onco.cc/technologies/fertility-preservation/>, <https://onco.cc/technologies/financial-navigation/>, <https://onco.cc/technologies/cbt-fatigue-distress/>, <https://onco.cc/technologies/exercise-during-chemotherapy/>, <https://onco.cc/technologies/multidisciplinary-tumour-board/>, <https://onco.cc/technologies/oncology-nutrition/>, <https://onco.cc/technologies/prehabilitation/>, <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/cytogenetics-fish/>, <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/clonality-testing/> ;
  onco:targets <https://onco.cc/targets/btk/>, <https://onco.cc/targets/bcl2/>, <https://onco.cc/targets/cd19/>, <https://onco.cc/targets/cd20/>, <https://onco.cc/targets/cd3/>, <https://onco.cc/targets/cdk4-6/>, <https://onco.cc/targets/ccnd1/>, <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/atm/>, <https://onco.cc/targets/plcg2/>, <https://onco.cc/targets/notch1/>, <https://onco.cc/targets/notch2/>, <https://onco.cc/targets/kmt2d/>, <https://onco.cc/targets/birc3/>, <https://onco.cc/targets/cdkn2a/> ;
  onco:drugs <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/acalabrutinib/>, <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/pirtobrutinib/>, <https://onco.cc/drugs/brexucabtagene-autoleucel/>, <https://onco.cc/drugs/lisocabtagene-maraleucel/>, <https://onco.cc/drugs/sonrotoclax/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/glofitamab/>, <https://onco.cc/drugs/clonoseq/>, <https://onco.cc/drugs/bortezomib/> ;
  onco:companies <https://onco.cc/companies/abbvie/>, <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/beone/>, <https://onco.cc/companies/gilead/>, <https://onco.cc/companies/eli-lilly/>, <https://onco.cc/companies/bms/> ;
  onco:pathways <https://onco.cc/pathways/apoptosis-bcl2/>, <https://onco.cc/pathways/p53-cell-cycle/>, <https://onco.cc/pathways/cell-cycle-engine-cdks/>, <https://onco.cc/pathways/bcr-signalling/>, <https://onco.cc/pathways/p53-mdm2-axis/> ;
  onco:terms <https://onco.cc/terms/del17p-tp53/>, <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/lugano-classification/>, <https://onco.cc/terms/mipi/>, <https://onco.cc/terms/cyclin-d1-t11-14/>, <https://onco.cc/terms/lymphoma-tx-transplant-role/>, <https://onco.cc/terms/lymphoma-tx-maintenance/>, <https://onco.cc/terms/lymphoma-tx-car-t-pathway/>, <https://onco.cc/terms/lymphoma-tx-crs-icans/>, <https://onco.cc/terms/lymphoma-tx-uk-versus-us/>, <https://onco.cc/terms/lymphoma-tx-regimen-alphabet/>, <https://onco.cc/terms/lymphoma-tx-tumour-lysis/>, <https://onco.cc/terms/cancer-related-fatigue/>, <https://onco.cc/terms/late-effects/>, <https://onco.cc/terms/febrile-neutropenia/>, <https://onco.cc/terms/neutropenia/>, <https://onco.cc/terms/financial-toxicity/>, <https://onco.cc/terms/central-venous-access/>, <https://onco.cc/terms/hypogammaglobulinaemia/>, <https://onco.cc/terms/performance-status/>, <https://onco.cc/terms/quality-of-life/>, <https://onco.cc/terms/lymphoma-decision-watch-and-wait/>, <https://onco.cc/terms/lymphoma-decision-local-or-car-t-centre/>, <https://onco.cc/terms/lymphoma-decision-trial/>, <https://onco.cc/terms/lymphoma-living-indolent-lymphoma/>, <https://onco.cc/terms/lymphoma-living-infection-years-after/>, <https://onco.cc/terms/lymphoma-living-vaccinations/>, <https://onco.cc/terms/lymphoma-living-fatigue/>, <https://onco.cc/terms/watchful-waiting/>, <https://onco.cc/terms/lymphoma-bio-antigen-escape/>, <https://onco.cc/terms/lymphoma-bio-germinal-centre/>, <https://onco.cc/terms/resistance/>, <https://onco.cc/terms/cross-resistance/> ;
  onco:trials <https://onco.cc/trials/nct07377578/>, <https://onco.cc/trials/nct04002297/>, <https://onco.cc/trials/nct01804686/>, <https://onco.cc/trials/nct06742996/>, <https://onco.cc/trials/nct06363994/>, <https://onco.cc/trials/nct04662255/>, <https://onco.cc/trials/nct02972840/>, <https://onco.cc/trials/zuma-2/>, <https://onco.cc/trials/triangle/>, <https://onco.cc/trials/sympatico/>, <https://onco.cc/trials/shine/>, <https://onco.cc/trials/enrich/>, <https://onco.cc/trials/lyma/> ;
  onco:pipeline <https://onco.cc/drugs/sonrotoclax/>, <https://onco.cc/drugs/glofitamab/>, <https://onco.cc/drugs/pirtobrutinib/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/bgb-16673/>, <https://onco.cc/drugs/nemtabrutinib/>, <https://onco.cc/drugs/rocbrutinib/>, <https://onco.cc/drugs/icp-248/>, <https://onco.cc/drugs/zamtocabtagene-autoleucel/>, <https://onco.cc/drugs/ctx112/> ;
  onco:standardOfCare <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/trials/triangle/>, <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/acalabrutinib/>, <https://onco.cc/drugs/acalabrutinib/>, <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/trials/sympatico/>, <https://onco.cc/drugs/brexucabtagene-autoleucel/>, <https://onco.cc/drugs/lisocabtagene-maraleucel/>, <https://onco.cc/drugs/pirtobrutinib/>, <https://onco.cc/drugs/sonrotoclax/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/terms/mipi/>, <https://onco.cc/terms/lymphoma-tx-watch-and-wait/>, <https://onco.cc/terms/lymphoma-tx-regimen-alphabet/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/trials/triangle/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/cytarabine/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/dexamethasone/>, <https://onco.cc/drugs/oxaliplatin/>, <https://onco.cc/terms/r-chop/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/terms/lymphoma-tx-transplant-role/>, <https://onco.cc/terms/lymphoma-tx-maintenance/>, <https://onco.cc/terms/lymphoma-tx-uk-access/>, <https://onco.cc/terms/mipi/>, <https://onco.cc/key-papers/paper-triangle-ibrutinib-mantle-cell-lymphoma-dreyling-lancet-2024/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/drugs/acalabrutinib/>, <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/bortezomib/>, <https://onco.cc/terms/r-chop/>, <https://onco.cc/terms/lymphoma-tx-uk-versus-us/>, <https://onco.cc/terms/lymphoma-tx-maintenance/>, <https://onco.cc/terms/lymphoma-tx-regimen-alphabet/>, <https://onco.cc/trials/sympatico/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/acalabrutinib/>, <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/bortezomib/>, <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/terms/lymphoma-tx-tumour-lysis/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/trials/zuma-2/>, <https://onco.cc/drugs/brexucabtagene-autoleucel/>, <https://onco.cc/drugs/lisocabtagene-maraleucel/>, <https://onco.cc/drugs/pirtobrutinib/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/glofitamab/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/terms/lymphoma-tx-car-t-pathway/>, <https://onco.cc/terms/lymphoma-tx-crs-icans/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/technologies/palliative-radiotherapy/>, <https://onco.cc/key-papers/paper-zuma-2-brexu-cel-mantle-cell-nejm-2020/> .